Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
Cochrane Database of Systematic ReviewsPublished 22 April 2002Open access
R G Miller, JD Mitchell, Mary Lyon, DH Moore
Citations910
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Riluzole 100 mg daily is reasonably safe and probably prolongs survival by about two months in patients with amyotrophic lateral sclerosis.
Abstract
Riluzole 100 mg daily is reasonably safe and probably prolongs survival by about two months in patients with amyotrophic lateral sclerosis. More studies are needed, especially to clarify its effect in older patients (over 75 years), and those with more advanced disease.
Keywords
ChemistryMedicine
Statistics in MedicineExtracting summary statistics to perform meta-analyses of the published literature for survival endpoints
4,783 Citations1998Mahesh Parmar, Valter Torri +1 more
A number of methods of extracting estimates of the log hazard ratio and its variance in a variety of situations are presented to improve the efficiency and reliability of meta-analyses of the published literature with survival-type endpoints.
Assessing Risk of Bias in Included Studies
3,156 Citations2008Julian P. T. Higgins, Douglas G. Altman
New England Journal of MedicineA Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis
2,157 Citations1994Gilbert Bensimon, Lucette Lacomblez +1 more
The antiglutamate agent riluzole appears to slow the progression of amyotrophic lateral sclerosis, and it may improve survival in patients with disease of bulbar onset, according to a prospective, double-blind, placebo-controlled trial in 155 outpatients with Amyotrophicateral sclerosis.
The LancetDose-ranging study of riluzole in amyotrophic lateral sclerosis
1,281 Citations1996Lucette Lacomblez, Gilbert Bensimon +4 more
A double-blind, placebo-controlled, multicentre study to confirm that riluzole is well tolerated and lengthens survival of patients with ALS, and suggests that the 100 mg dose of rILuzole has the best benefit-to-risk ratio.
The Lancet NeurologyEffects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial
1,147 Citations2006Stephen C Bourke, Mark Tomlinson +4 more
In patients with amyotrophic lateral sclerosis without severe bulbar dysfunction, NIV improves survival with maintenance of, and improvement in, quality of life and the survival benefit from NIV in this group is much greater than that from currently available neuroprotective therapy.
NeurologyPractice Parameter update: The care of the patient with amyotrophic lateral sclerosis: Drug, nutritional, and respiratory therapies (an evidence-based review)[RETIRED]
808 Citations2009Robert G. Miller, Carlayne E. Jackson +11 more
More studies are needed to examine the best tests of respiratory function in ALS, as well as the optimal time for starting PEG, the impact of PEG on quality of life and survival, and the effect of vitamins and supplements on ALS.
NeurologyPractice parameter: The care of the patient with amyotrophic lateral sclerosis (an evidence-based review) [RETIRED]
575 Citations1999Robert G. Miller, J. Rosenberg +12 more
This evidence-based review addresses some of the major management issues in patients with ALS, and highlights the many areas in which more research is needed, as well as developing practice parameters for physicians.
NeurologyPrognostic indicators of survival in ALS
250 Citations1998Nancy Stambler, Matthew Charatan +2 more
Serum chloride, reflecting the degree of respiratory acidosis, was identified for the first time as being correlated with prognosis in ALS, and was associated with shorter survival times.
Archives of NeurologyAn Analysis of Extended Survival in Patients With Amyotrophic Lateral Sclerosis Treated With Riluzole
199 Citations1998Marc Rivière, Vincent Meininger +2 more
A significant difference in the time to transit between the riluzole and the placebo groups in less severely affected cases was showed, ie, state 2 and state A (the milder states) of ALS.
Journal of Neural TransmissionHigh dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study
191 Citations2004Michael Graf, D. Ecker +31 more
Neither the primary nor the secondary outcome measures could determine whether a megadose of vitamin E is efficacious in slowing disease progression in ALS as an add-on therapy to riluzol.
NeuroreportRecovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy
179 Citations1998Sanjay Kalra, Neil R. Cashman +2 more
Journal of NeurologyA study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis
171 Citations2002Gilbert Bensimon, Lucette Lacomblez +4 more
Riluzole was well-tolerated in this patient population, and the adverse events observed were similar in nature and frequency to those observed in previously published clinical trials in patients included in pivotal trials.
Amyotrophic Lateral Sclerosis and Other Motor Neuron DisordersEfficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials
130 Citations2004Vincent Meininger, Gilbert Bensimon +7 more
European Journal of NeurologyRiluzole and amyotrophic lateral sclerosis survival: a population‐based study in southern Italy
122 Citations2007Stefano Zoccolella, Ettore Beghi +10 more
In this population‐based series, riluzole therapy improves ALS survival and is effective amongst cases with bulbar‐onset ALS and older patients, but not in subjects with limb-onset.
Amyotrophic Lateral Sclerosis and Other Motor Neuron DisordersPrognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis
95 Citations2002Martin R. Turner, Marjan Bakker +4 more
Clinical databases can be used to generate multivariate prognostic models in ALS to predict survival, to improve criteria for matching of patients in future clinical trials, and to test the impact of interventions.
Health Technology AssessmentThe clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: a rapid and systematic review
88 Citations2001Antony Stewart, Josie Sandercock +5 more
NeurologyRelationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS
71 Citations1996Dawn McGuire, Louis P. Garrison +8 more
There was a significant relationship between TQNE and SIP scores, both in cross section and over time, which strongly relate to ALS patients' quality of life and ability to perform activities of daily living.
NeurologyClinical trials of riluzole in patients with ALS
71 Citations1996Robert G. Miller, J.P. Bouchard +9 more
Two double-blinded, placebo-controlled clinical trials of riluzole have now been carried out in more than 1,100 patients with ALS, showing a modest benefit in prolonging survival that is statistically significant.
Current Opinion in NeurobiologyTherapeutic horizons for amyotrophic lateral sclerosis
65 Citations1996Jeffrey D. Rothstein
Clinical and preclinical studies have now provided the first agents that reproducibly alter the course of amyotrophic lateral sclerosis.
NeurologyA double‐blind, placebo‐controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis
64 Citations1989Lucette Lacomblez, P. Bouché +2 more
Though this dosage had no major toxic effect, Cronassial treatment did not significantly benefit ALS patients and was not effective in any of the outpatients.
NeurologyPractice advisory on the treatment of amyotrophic lateral sclerosis with riluzole: Report of the Quality Standards Subcommittee of the American Academy of Neurology [RETIRED]
51 Citations1997Quality Standards Subcommittee of the American Academy of Neurology
Riluzole has a modulating effect on glutamatergic transmission and demonstrates modest prolongation of survival without tracheostomy in ALS patients.
Amyotrophic Lateral SclerosisAudit of outcomes in motor neuron disease (MND) patients treated with riluzole
51 Citations2006Douglas Mitchell, Mary O’Brien +1 more
Results illustrate the desirability of controlled introduction of new drugs into clinical practice when RCTs have only suggested a modest level of efficacy and emphasize the importance of adequate randomized studies being completed prior to licensing of newdrugs.
Journal of NeurologyWhat has changed with riluzole?
43 Citations2000Vincent Meininger, Lucette Lacomblez +1 more
Riluzole provides a hope for slowing down the rate of evolution and abolishes the myth of “no hope, no cure” of patients care, and other information have been published supporting the probable activity of the drug on the muscle strength decline, a controversial matter.
New England Journal of MedicineRiluzole for the Treatment of Amyotrophic Lateral Sclerosis -- Too Soon to Tell?
39 Citations1994Lewis P. Rowland
It is reported in this issue of the Journal that riluzole, a glutamate antagonist, increased survival in one group of patients with amyotrophic lateral sclerosis (ALS) but was not helpful in another group of Patients with the same disease.
Journal of HepatologyAcute hepatitis after riluzole administration
37 Citations1999André‐Jean Remy, William Camu +3 more
It is suggested that riluzole can induce acute hepatitis with associated hepatocellular damage and microvesicular steatosis and liver enzymes should be monitored during treatment with rILuzole.
Journal of the Neurological SciencesThe effect of riluzole in amyotrophic lateral sclerosis: a study with cortical stimulation
30 Citations1999M.T. Desiato, Maria Giuseppina Palmieri +4 more
The neurophysiological contribution to the assessment of the effect of riluzole on the motor cortical inhibitory property in ALS may be considered a setting for controlled trials in extended patient series, even in a pre-clinical phase.
NeurologyALS therapy
25 Citations1996Jacques Hugon
Protection against excitotoxicity could be achieved with a combination of pharmacologic agents having neuroprotective activity, such as antiglutamate agents, N-methyl-D-aspartate and non-NMDA antagonists, free-radical scavengers, calcium-channel blockers, and neurotrophic factors.
PubMedRiluzole and ALS therapy.
23 Citations1996Jacques Hugon
Riluzole is an anti-convulsant and a neuroprotective agent and specifically blocks sodium channels in their inactivated states and prolonged survival was significant in the overall population and in the bulbar-onset group.
Journal of the Neurological SciencesGerman open label trial of riluzole 50 mg b.i.d. in treatment of amyotrophic lateral sclerosis (ALS)
22 Citations2000D. Pongratz, B. Neundörfer +1 more
Overall the safety profile found in the German centres was very similar to the profile seen in the total patient population and was more favourable than in the two published double-blind studies.
The LancetEffects of riluzole on symptom progression in amyotrophic lateral sclerosis
22 Citations1997Peter Sojka, P. M. Andersen +1 more
Dinamap and the random-zero sphygmomanometer cannot be used interchangeably in adult diabetic patients and for both systolic and diastolic BP the degree of agreement as indicated by the Bland and Altman analysis is not ideal.
NeurologyHypersensitivity pneumonitis possibly caused by riluzole therapy in ALS
22 Citations2003David Cassiman, Michiel Thomeer +2 more
A 69-year-old man with sporadic amyotrophic lateral sclerosis presented with complaints of increasing and disabling shortness of breath and dry cough for 3 months, and clinical examination revealed ALS with predominant lower limb involvement.
Journal of NeurologyThe Riluzole Early Access Programme: descriptive analysis of 844 patients in France
19 Citations1997Vincent Meininger, Michel Dib +3 more
It is shown that riluzole prolongs tracheostomy-free survival in outpatients with amyotrophic lateral sclerosis and compares favourably with that achieved therapeutically in breast cancer and coronary artery disease.
NeurologyRiluzole-induced neutropenia
12 Citations2004Regina Weber, Haim Bitterman
A patient who developed severe neutropenia in association with a standard dose (100 mg/d) of riluzole is reported, which is an extremely rare, not well-described, life-threatening adverse reaction of the drug.
NeurologyAn acute, life-threatening, hypersensitivity reaction to riluzole
12 Citations2006Eric J. Sorenson
A severe, life-threatening systemic inflammatory reaction to riluzole is reported in a patient with ALS, the only Food and Drug Administration–approved treatment of ALS that has been shown to modestly prolong survival.
Archivos de BronconeumologíaAlta sospecha de toxicidad pulmonar por riluzol
10 Citations2006Luis Borderías, J. Garrapiz-López +4 more
La coincidencia en el tiempo, the falta de respuesta al tratamiento antibiotico, the ausencia of diagnosticos alternativos y hallazgos clinicos y radiologicos indicatives apuntan a la toxicidad por el riluzol.
PubMed[Interest of a computerized ALS database in the diagnosis and follow-up of patients with ALS].
9 Citations2000Philippe Couratier, Michel Druet‐Cabanac +5 more
A computerized database of the Neurology department of Limoges University Hospital and the main results obtained from data of 340 patients suffering from amyotrophic lateral sclerosis, diagnosed between 1984 and 1997 are presented.
Archivos de BronconeumologíaStrong Suspicion of Lung Toxicity Due to Riluzole
7 Citations2006Luis Borderías, J. Garrapiz-López +4 more
The coincidence in time, lack of response to antibiotic treatment, remission of symptoms following withdrawal of the drug without initiating any other treatment except 40 mg/d of methylprednisolone for 6 days, absence of alternative diagnoses, and suggestive clinical and radiologic findings all together point to toxicity due to riluzole.
Aktuelle NeurologieOffene Therapiestudie zur Verträglichkeit von Riluzol bei Patienten mit amyotropher Lateralsklerose (ALS)
6 Citations1999D. Pongratz, B. Neundörfer
Journal of the Peripheral Nervous SystemAN OPEN STUDY OF RILUZOLE VERSUS RILUZOLE PLUS GABAPENTIN IN AMYOTROPHIC LATERAL SCLEROSIS
5 Citations2000V. Palma, Vincenzo Brescia Morra +3 more
There was no significant difference in response to treatment when severity and duration of the disease were compared in the two groups, and there were no significant differences in response for riluzole plus gabapentin at the initial dose of 300 mg/day.